Gregory M Enns, MD
Medical Genetics and Genomics · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 2
Offices
2 locations · Lpch Medical Group Div of Lucile · Kapiolani Medical Specialists
Looking this up.
Hospitals listed: Lucile Salter Packard Children'S Hsp at Stanford. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Enns’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A52095 · Current
Licensed to practise in California · since 1993 · expires 2027-01-31 · University of Glasgow Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Lucile Salter Packard Children'S Hsp at StanfordPalo Alto, CAChildren · Voluntary non-profit - Private · No emergency departmentPart of Stanford Health Care, which runs 3 hospitalsNo overall ratingNo measure marked better or worse than the national rate
Original Medicare doctor bills
$1,379
Medicare paid this office $1,379 for 13 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
13 Original Medicare patients in 2024. Average age 63 · 85 and older 0% · Health risk score 1.20. At or below the middle of the specialty; the typical medical genetics and genomics clinician is at 1.41.
The office billed $5,238, Medicare allowed $2,088 and paid $1,379; for 13 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 13 | 13 | 63 | 1.20 | $5,238 | $1,379 |
| 2023 | 18 | 25 | 57 | 1.05 | $8,828 | $2,341 |
| 2022 | 13 | 15 | 53 | 0.99 | $6,176 | $1,595 |
| 2018 | 11 | 12 | 48 | 1.45 | $2,429 | $756 |
| 2013 | 12 | 19 | 48 | 0.99 | $5,917 | $1,572 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
Medicaid work
$6,723 in 2024
Medicaid paid $6,723 for 48 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 36 | $5,397 |
| Return visit (30+ min) | 12 | $1,326 |
| 2024 | 48 | 2 | 18 | $6,723 |
| 2023 | 65 | 3 | 18 | $6,035 |
| 2022 | 15 | 1 | 13 | $1,827 |
| 2021 | 14 | 1 | 12 | $1,105 |
| 2020 | 42 | 2 | 15 | $3,962 |
| 2019 | 28 | 2 | 14 | $1,279 |
| 2018 | 79 | 3 | 16 | $5,178 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 30 | $3,844 |
| Service | 18 | $1,283 |
| Service | 17 | $909 |
2022
| Long return visit (40+ min) | 15 | $1,827 |
2021
| Return visit (30+ min) | 14 | $1,105 |
2020
| Long return visit (40+ min) | 15 | $2,046 |
| Return visit (30+ min) | 27 | $1,917 |
2019
| Service | 14 | $731 |
| Service | 14 | $548 |
2018
| Return visit (30+ min) | 42 | $2,755 |
| Service | 25 | $1,782 |
| Service | 12 | $642 |
Money from drug and device companies
$5,275 in 2025
| 2025 | 4 | 5 | $5,258 | $5,275 |
| 2024 | 3 | 3 | $1,525 | $1,525 |
| 2023 | 3 | 5 | $9,794 | $9,794 |
| 2022 | 4 | 12 | $15,213 | $15,213 |
| 2021 | 4 | 12 | $14,444 | $14,534 |
| 2020 | 4 | 34 | $26,938 | $27,028 |
| 2019 | 3 | 21 | $13,735 | $14,972 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amicus Therapeutics | Pombiliti | $2,490 | 2 payments
|
| Ucb Sa | None | $2,288 | 1 payment
|
| Tanabe Pharma America | None | $480 | 1 payment
|
| Immedica Pharma US | None | $18 | 1 payment
|
See all 5 published payments
| Amicus Therapeutics | Consulting · 2025-08-06 | Pombiliti | $915 |
| Immedica Pharma US | Meals · 2025-07-24 | None | $18 |
| Ucb Sa | Consulting · 2025-06-20 | None | $2,288 |
| Amicus Therapeutics | Consulting · 2025-02-05 | Pombiliti | $1,575 |
| Tanabe Pharma America | Consulting · 2025-01-16 | None | $480 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,525
| Ucb Sa | None | $900 | 1 payment
|
| Mitsubishi Tanabe Pharma America | None | $400 | 1 payment
|
| Mirum Pharmaceuticals | Cholbam | $225 | 1 payment
|
2023: $9,794
| Travere Therapeutics | Cholbam | $6,650 | 2 payments
|
| Ucb Sa | None | $1,611 | 1 payment
|
| Amicus Therapeutics | Pombiliti | $1,533 | 2 payments
|
2022: $15,213
| ModernaTX | None | $6,300 | 2 payments
|
| Horizon Therapeutics plc | Ravicti | $5,250 | 1 payment
|
| Travere Therapeutics | Cholbam | $1,863 | 6 payments
|
| Amicus Therapeutics | None | $1,800 | 2 payments
|
2021: $14,534
| Horizon Therapeutics plc | Ravicti | $9,494 | 3 payments
|
| Amicus Therapeutics | None | $2,700 | 2 payments
|
| Travere Therapeutics | Cholbam | $2,250 | 4 payments
|
| Ultragenyx Pharmaceutical | Dojolvi | $90 | 3 payments
|
2020: $27,028
| Ultragenyx Pharmaceutical | Dojolvi | $8,890 | 7 payments
|
| Travere Therapeutics | (820) Cholbam | $7,313 | 16 payments
|
| Amicus Therapeutics | None | $6,275 | 9 payments
|
| Horizon Therapeutics plc | Ravicti | $4,550 | 2 payments
|
2019: $14,972
| Retrophin | (820) Cholbam | $11,763 | 12 payments
|
| BioMarin Pharmaceutical | Kuvan | $2,198 | 1 payment
|
| Horizon Therapeutics plc | Ravicti | $1,012 | 8 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ModernaTX, Inc. · An Extension Study To Evaluate the Long-Term Safety and Clinical Activity of Mrna-3705 in Participants Previously Enrolled in Other Clinical Studies of Mrna-3705 · 2025 | Their institution | $290,479 |
| PTC Therapeutics, Inc. · An Open-Label, Safety Study for Previously Treated Vatiquinone (Ptc743) Subjects With Inherited Mitochondrial Disease · 2024 | Their institution | $71,374 |
| PTC Therapeutics, Inc. · Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy · 2022 | Their institution | $56,391 |
| ModernaTX, Inc. · A Global, Phase 1/2, Open-Label, Dose Optimization Study To Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Mrna 3705 in Participants With Isolated Methylmalonic Acidemia Due To Methylmalonyl-Coa Mutase Deficiency · 2024 | Their institution | $46,703 |
| PTC Therapeutics, Inc. · An Open-Label, Safety Study for Previously Treated Vatiquinone (Ptc743) Subjects With Inherited Mitochondrial Disease · 2023 | Their institution | $44,970 |
| PTC Therapeutics, Inc. · Long-Term Safety and Efficacy Evaluation of Vatiquinone (Epi-743) in Children With Leigh Syndrome · 2020 | Their institution | $39,820 |
| Saol International Limited · Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency: (Dca/Pdcd) · 2021 | Their institution | $39,738 |
| PTC Therapeutics, Inc. · Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy · 2021 | Their institution | $39,179 |
| ModernaTX, Inc. · A Global, Phase 1/2, Open-Label, Dose Optimization Study To Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Mrna 3705 in Participants With Isolated Methylmalonic Acidemia Due To Methylmalonyl-Coa Mutase Deficiency · 2023 | Their institution | $36,673 |
| ModernaTX, Inc. · A Global, Phase 1/2, Open-Label, Dose Optimization Study To Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of Mrna 3927 in Participants With Propionic Acidemia · 2023 | Their institution | $36,267 |
| PTC Therapeutics, Inc. · Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy · 2023 | Their institution | $34,583 |
| PTC Therapeutics, Inc. · Emergency Use Protocol for Epi-743 in Acutely Ill Patients Inherited Mitochondrial Respiratory Chain Disease Within 90 Days of End-of-Life-Care · 2021 | Their institution | $29,492 |
| PTC Therapeutics, Inc. · An Open-Label, Safety Study for Previously Treated Vatiquinone (Ptc743) Subjects With Inherited Mitochondrial Disease · 2025 | Their institution | $28,678 |
| PTC Therapeutics, Inc. · Long-Term Safety and Efficacy Evaluation of Vatiquinone (Epi-743) in Children With Leigh Syndrome · 2022 | Their institution | $25,808 |
| Astellas Pharma Inc · A Randomized, Double-Blind, Placebo-Controlled Adaptive Phase 2/3 Study With Open-Label Extension To Assess the Efficacy, Safety and Tolerability of Asp0367 in Participants With Primary Mitochondrial Myopathy · 2023 | Their institution | $25,431 |
| Astellas Pharma Inc · A Randomized, Double-Blind, Placebo-Controlled Adaptive Phase 2/3 Study With Open-Label Extension To Assess the Efficacy, Safety and Tolerability of Asp0367 in Participants With Primary Mitochondrial Myopathy · 2024 | Their institution | $24,428 |
| Astellas Pharma Inc · A Randomized, Double-Blind, Placebo-Controlled Adaptive Phase 2/3 Study With Open-Label Extension To Assess the Efficacy, Safety and Tolerability of Asp0367 in Participants With Primary Mitochondrial Myopathy · 2021 | Their institution | $22,701 |
| ModernaTX, Inc. · A Study To Assess Safety, Pharmacokinetics, and Pharmacodynamics of Mrna-3705 in Participants With Isolated Methylmalonic Acidemia · 2025 | Their institution | $20,258 |
| Travere Therapeutics, Inc. · The Replace Registry · 2020 | Their institution | $18,252 |
| PTC Therapeutics, Inc. · Emergency Use Protocol for Epi-743 in Acutely Ill Patients Inherited Mitochondrial Respiratory Chain Disease Within 90 Days of End-of-Life-Care · 2022 | Their institution | $17,055 |
| PTC Therapeutics, Inc. · Long-Term Safety and Efficacy Evaluation of Vatiquinone (Epi-743) in Children With Leigh Syndrome · 2021 | Their institution | $13,282 |
| ModernaTX, Inc. · US-Based Retrospective Medical Record Review of Patients With Methylmalonic Acidemia (Mma) Undergoing Liver Or Combined Liver-Kidney Transplants (Lt/Lkt) · 2025 | Their institution | $12,895 |
| ModernaTX, Inc. · Open-Label Study of Mrna-3927 in Participants With Propionic Acidemia · 2025 | Their institution | $10,927 |
| Horizon Therapeutics plc · Long-Term Registry of Patients With Urea Cycle Disorders (Ucds) · 2020 | Their institution | $10,360 |
| Takeda Pharmaceuticals U.S.A., Inc. · Observational, Real World Assessment of Long Term Safety and Effectiveness of Gaucher Disease · 2021 | Their institution | $9,343 |
| PTC Therapeutics, Inc. · Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy · 2024 | Their institution | $8,808 |
| Saol International Limited · Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency: (Dca/Pdcd) · 2022 | Their institution | $8,774 |
| Takeda Pharmaceuticals U.S.A., Inc. · Gaucher Disease Outcome Survey (Gos) An Observational, International, Multicenter, Long-Term Registry of Patients With Gaucher Disease · 2025 | Their institution | $8,492 |
| PTC Therapeutics, Inc. · Emergency Use Protocol for Epi-743 in Acutely Ill Patients With Inherited Mitochondrial Respiratory Chain Disease Within 90 Days of End-of-Life Care · 2025 | Their institution | $8,366 |
| Astellas Pharma Inc · A Randomized, Double Blind, Placebo Controlled Adaptive Phase 2/3 Study With Open Label Extension To Assess the Efficacy, Safety and Tolerability of Asp0367 in Participants With Primary Mitochondrial Myopathy · 2025 | Their institution | $7,553 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Global, Multi-Center, Long-Term, Observational Survey of Patients With Hunter Syndrome Mucopolysaccharidosis II · 2021 | Their institution | $5,342 |
| PTC Therapeutics, Inc. · Long-Term Safety and Efficacy Evaluation of Vatiquinone (Epi-743) in Children With Leigh Syndrome · 2023 | Their institution | $5,341 |
| BioMarin Pharmaceutical Inc. · Pku Demographics, Outcomes, and Safety Registry · 2019 | Their institution | $5,200 |
| Takeda Pharmaceuticals U.S.A., Inc. · Gaucher Disease Outcome Survey (Gos) An Observational, International, Multicenter, Long-Term Registry of Patients With Gaucher Disease · 2023 | Their institution | $4,886 |
| Travere Therapeutics, Inc. · The Replace Registry · 2021 | Their institution | $4,855 |
| Alexion Pharmaceuticals, Inc. · Lysosomal Acid Lipase (Lal) Deficiency Registry (Alx-Lald-501) · 2020 | Their institution | $4,726 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Global, Multi-Center, Long-Term, Observational Survey of Patients With Hunter Syndrome Mucopolysaccharidosis II · 2020 | Their institution | $4,366 |
| Shire North American Group Inc · Observational, Real World Assessment of Long Term Safety and Effectiveness of Gaucher Disease · 2019 | Their institution | $3,840 |
| Mirum Pharmaceuticals, Inc. · A Prospective, Observational, Non-Interventional, Post-Marketing, Patient Registry To Collect Data on Routine Clinical Care in Patients Treated With Cholbam (Cholic Acid) (Replace) · 2025 | Their institution | $3,830 |
| Travere Therapeutics, Inc. · The Replace Registry · 2023 | Their institution | $3,250 |
| Ultragenyx Pharmaceutical Inc. · Ux007-Cl003 · 2019 | Their institution | $3,250 |
| Mirum Pharmaceuticals, Inc. · A Prospective, Observational, Non-Interventional, Post-Marketing, Patient Registry To Collect Data on Routine Clinical Care in Patients Treated With Cholbam (Cholic Acid) (Replace) · 2023 | Their institution | $3,130 |
| Mirum Pharmaceuticals, Inc. · A Prospective, Observational, Non-Interventional, Post-Marketing, Patient Registry To Collect Data on Routine Clinical Care in Patients Treated With Cholbam (Cholic Acid) (Replace) · 2024 | Their institution | $2,495 |
| Takeda Pharmaceuticals U.S.A., Inc. · Hunter Outcome Survey: A Global, Multi-Center, Long-Term, Observational Registry of Patients With Hunter Syndrome (Mucopolysaccharidosis Type II, Mps II) · 2024 | Their institution | $2,343 |
| Travere Therapeutics, Inc. · The Replace Registry · 2022 | Their institution | $2,255 |
| ModernaTX, Inc. · A Global, Phase 1/2, Open-Label, Dose Optimization Study To Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of Mrna 3927 in Participants With Propionic Acidemia · 2022 | Their institution | $2,213 |
| PTC Therapeutics, Inc. · Emergency Use Protocol for Epi-743 in Acutely Ill Patients Inherited Mitochondrial Respiratory Chain Disease Within 90 Days of End-of-Life-Care · 2023 | Their institution | $2,185 |
| Astellas Pharma Inc · A Randomized, Double-Blind, Placebo-Controlled Adaptive Phase 2/3 Study With Open-Label Extension To Assess the Efficacy, Safety and Tolerability of Asp0367 in Participants With Primary Mitochondrial Myopathy · 2022 | Their institution | $2,100 |
| Takeda Pharmaceuticals U.S.A., Inc. · Hunter Outcome Survey: A Global, Multi-Center, Long-Term, Observational Registry of Patients With Hunter Syndrome (Mucopolysaccharidosis Type II, Mps II) · 2023 | Their institution | $1,716 |
| Horizon Therapeutics plc · Long-Term Registry of Patients With Urea Cycle Disorders Ucds · 2019 | Their institution | $1,656 |
| Alexion Pharmaceuticals, Inc. · Lysosomal Acid Lipase Lal Deficiency Registry Alx-Lald-501 · 2019 | Their institution | $1,520 |
| Takeda Pharmaceuticals U.S.A., Inc. · Observational, Real World Assessment of Long Term Safety and Effectiveness of Gaucher Disease · 2022 | Their institution | $1,280 |
| Takeda Pharmaceuticals U.S.A., Inc. · Observational, Real World Assessment of Long Term Safety and Effectiveness of Gaucher Disease · 2020 | Their institution | $1,280 |
| Retrophin, Inc. · The Replace Registry · 2019 | Their institution | $1,092 |
| SANOFI US SERVICES INC. · Gaucher Disease Registry Protocol · 2023 | Their institution | $950 |
| PTC Therapeutics, Inc. · Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy · 2020 | Their institution | $706 |
| Ultragenyx Pharmaceutical Inc. · Ux007-Cl003 · 2020 | Their institution | $650 |
| Travere Therapeutics, Inc. · A Prospective, Observational, Non-Interventional, Post-Marketing, Patient Registry To Collect Data on Routine Clinical Care in Patients Treated With Cholbam (Cholic Acid) · 2023 | Their institution | $425 |
| Alexion Pharmaceuticals, Inc. · An Observational Disease and Clinical Outcomes Registry of Patients With Lysosomal Acid Lipase (Lal) Deficiency · 2021 | Their institution | $390 |
| Alexion Pharmaceuticals, Inc. · An Observational Disease and Clinical Outcomes Registry of Patients With Lysosomal Acid Lipase (Lal) Deficiency · 2022 | Their institution | $310 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 85.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1508961897
- Licence
- CA A52095, HI MD-12592California A52095: Current · expires 2027-01-31
- Group
- Lpch Medical Group Div of Lucile · Kapiolani Medical Specialists
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207SG0207X (207SG0207X); Federal specialty code 207SG0201X (207SG0201X); Federal specialty code 207SG0202X (207SG0202X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2006-09-13
- NPI last updated
- 2024-04-09
- NPI record certified
- 2024-04-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, H315, Palo Alto, CA, 94305